ACM
VKTX icon

Asymmetry Capital Management’s Viking Therapeutics VKTX Stock Holding History

Asymmetry Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-154,207
Closed -$1.46M – 44
2018
Q2 		$1.46M Buy
+154,207
New +$1.03M 1.44% 25

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Asymmetry Capital Management's VKTX Position: Q3 2018 in Review

Asymmetry Capital Management sold out of Viking Therapeutics (VKTX) in Q3 2018, closing a stake of 154,207 shares — an estimated $1.46M sold.

Asymmetry Capital Management first reported a position in VKTX in Q2 2018 and held it in 1 quarter. The position peaked at $1.46M in Q2 2018. 148 funds tracked by Wall St. Rank hold VKTX as of Q3 2018.

  • Asymmetry Capital Management reported no remaining Viking Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Asymmetry Capital Management sold 154,207 Viking Therapeutics shares in Q3 2018, an estimated $1.46M.
  • Asymmetry Capital Management first reported a position in Viking Therapeutics in Q2 2018 and held it in 1 quarter.
  • Asymmetry Capital Management's Viking Therapeutics position peaked at $1.46M in Q2 2018.
  • 148 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2018.

Based on Asymmetry Capital Management's 13F filing for Q3 2018, filed 8 Nov 2018.